INFORMATION ON JAPANESE REGULATORY AFFAIRS

Regulatory Information Task Force
Japan Pharmaceutical Manufacturers Association

Pharmaceutical Administration and Regulations in Japan

Japan Pharmaceutical Manufacturers Association
Pharmaceutical Administration and Regulations in Japan

This file contains information concerning pharmaceutical administration, regulations, and new drug development in Japan updated annually by the English RA Information Task Force, International Affairs Committee, Japan Pharmaceutical Manufacturers Association (JPMA). The contents are not abstracts of governmental rules or regulations but concise descriptions of most current practices by regulatory agencies and the industry that the working group complies. The file does not contain anything related to forecasts. The file is available also at the homepage of National Institute of Health Sciences (http://www.nihs.go.jp/kanren/iyaku.html).

Japan Pharmaceutical Manufacturers Association

http://www.jpma.or.jp/english/
# Table of Contents

**CHAPTER 1** ................................................................. 1

**ORGANIZATION AND FUNCTION OF THE MINISTRY OF HEALTH, LABOUR AND WELFARE** ........................................... 1

1. PHARMACEUTICAL SAFETY AND ENVIRONMENTAL HEALTH BUREAU (PSEHB) ............................................. 2
   1.1 General Affairs Division ........................................ 2
   1.2 Pharmaceutical Evaluation Division ........................... 2
   1.3 Medical Device Evaluation Division ........................... 2
   1.4 Safety Division .................................................... 3
   1.5 Compliance and Narcotics Division ............................ 3
   1.6 Blood and Blood Products Division ............................ 3

2. HEALTH POLICY BUREAU .............................................. 4
   2.1 Economic Affairs Division ....................................... 4
   2.2 Research and Development Division .......................... 4

3. NATIONAL INSTITUTE OF HEALTH SCIENCES .......................... 5

4. PHARMACEUTICALS AND MEDICAL DEVICES AGENCY (PMDA), AN INDEPENDENT ADMINISTRATIVE ORGANIZATION ........................................ 5
   4.1 Office of Review Administration ................................. 6
   4.2 Office of Review Management ................................. 6
   4.3 Office of Standards and Guidelines Development ............. 6
   4.4 Office of New Drug I ............................................. 6
   4.5 Office of New Drug II ............................................. 6
   4.6 Office of New Drug III ............................................. 6
   4.7 Office of New Drug IV ............................................ 7
   4.8 Office of New Drug V ............................................ 7
   4.9 Office of Cellular and Tissue-based Products .................. 7
   4.10 Office of Vaccines and Blood Products ....................... 7
   4.11 Office of OTC and Generics ................................. 7
   4.12 Office of Generics ............................................. 7
   4.13 Office of Medical Devices I .................................... 7
   4.14 Office of Medical Devices II .................................. 7
   4.15 Office of Medical Devices III ................................. 7
   4.16 Office of Compliance and Standards .......................... 7
   4.17 Office of Safety I ............................................... 8
   4.18 Office of Safety II ............................................... 8
   4.19 Office of Manufacturing/Quality and Compliance .......... 8
   4.20 Office of International Programs .............................. 8
   4.21 Advanced Review with Electronic Data Promotion Group .... 8
   4.22 Kansai Branch .................................................. 8
   4.23 Hokuriku Branch ............................................... 8

5. NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION (NIBION) ............................. 8

6. JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT (AMED) .................................................. 9

7. PHARMACEUTICAL AFFAIRS AND FOOD SANITATION COUNCIL (PAFSC) ................................................. 9

8. NATIONAL INSTITUTE OF INFECTIOUS DISEASES .................................................. 9

**CHAPTER 2** ................................................................ 15

**PHARMACEUTICAL LAWS AND REGULATIONS** .............................. 15

1. PHARMACEUTICAL LAWS ............................................. 15

2. PHARMACEUTICAL AND MEDICAL DEVICE ACT .......................... 15

3. OUTLINE OF PHARMACEUTICAL REGULATIONS ...................... 17
   3.1 Definition of Drugs ............................................... 17
   3.2 Definition of Drugs ............................................... 17
   3.3 License for Manufacturing/Marketing Businesses .............. 19
   3.4 License for Manufacturing Business and Accreditation of Overseas
Pharmaceutical Regulations in Japan:

Reactions and Infections during the Study .............................................. 56
1.4 Interview advice meetings ............... 57
1.5 Approval review .................................. 59
1.6 Compliance review .............................. 61
1.7 GMP compliance inspection .......... 62

2. DATA REQUIRED FOR APPROVAL APPLICATIONS ......................... 64
2.1 Data to be Attached to Approval Application of Drugs ..................... 67

3. GUIDELINES CONCERNING DRUG APPROVAL APPLICATIONS ............... 68
3.1 Nonclinical Studies ......................... 69
3.2 Clinical Studies ......................... 77

4. OTHER .......................................................... 88
4.1 Biotechnological Products ................... 88
4.2 Drugs Using Materials of Human or Animal Origin as Ingredients (Biological Products) ..................... 89
4.3 Biosimilar Products ...................... 90
4.5 ICH (International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use) ... 91

CHAPTER 4 ................................................................. 106
POST-MARKETING SURVEILLANCE OF DRUGS .............................................. 106

1. GVP .......................................................... 108
2. GPSP .................................................... 115
3. PAPER COMPLIANCE REVIEW AND ON-SITE GPSP SURVEYS OF DATA FOR REEXAMINATION AND REEVALUATION ............................................... 118
4. ADVERSE DRUG REACTIONS AND INFECTIONS REPORTING SYSTEM .... 119
4.1 Adverse Drug Reaction and Infectious Disease Reporting System by Pharmaceutical Companies ............................. 119
4.2 Drug and Medical Device Safety Information Reporting System by Medical Personnel ............................. 122
4.3 WHO International Drug Monitoring Program .............................................. 122

5. PERIODIC INFECTION REPORTS FOR BIOLOGICAL PRODUCTS (ARTICLE 68-14 AND 68-24 IN THE LAW) ................ 122

6. REEXAMINATION SYSTEM (ARTICLE 14-4 AND 23-29 OF THE PHARMACEUTICAL AFFAIRS LAW) ................. 123
6.1 Designation for Reexamination of Drugs .............................................. 123
6.2 Periodic Safety Reports (Article 63 of the Enforcement Regulations of the Law) .............................................. 124
6.3 Data Required for Reexamination Applications and Reexamination Procedures .............................................. 124

7. REEVALUATION SYSTEM (ARTICLES 14-6 AND 23-31 OF THE LAW) .......... 125

CHAPTER 5 ............................................................................. 132
SUPPLY AND DISSEMINATION OF DRUG SAFETY MANAGEMENT INFORMATION ... 132

1. PACKAGE INSERTS .................................................. 132
1.1 Guidance on the Style and Format of Package Inserts ......................... 134
1.2 Headings and Their Sequence in Package Inserts ................................. 135
1.3 Precautions ........................................................................ 136
1.4 Labeling of Excipients .................................................................. 137
1.5 Entries for Biological Products ...................................................... 138
1.6 Brand Names of Prescriptions Drugs .................................................. 138
1.7 Information on Package Inserts in English ......................................... 139

2. INFORMATION TO SUPPLEMENT PACKAGE INSERTS ......................... 139
2.1 Outline of Prescription
Pharmaceutical Regulations in Japan:

2.2 Pharmaceutical Interview Forms (IF) ................................ 140
3. SUPPLY AND DISSEMINATION OF SAFETY MANAGEMENT
   INFORMATION........................................ 140
   3.1 Distribution of Emergency Safety Information (Yellow Letters) .... 141
   3.2 Safety Flash Report (Blue Letters) 142
   3.3 Distribution of Information by 'Notices of Revision of Precautions' 143
   3.4 Dissemination of Information for Drugs That Have Completed Reexamination or Reevaluation .... 144
   3.5 Dissemination of ADR Information by the Pharmaceuticals and Medical Devices Safety Information (Information on Adverse Reactions to Drugs) ........................................ 144
   3.6 Dissemination of Information by Drug Safety Update .............. 144
   3.7 Commentaries on "Precautions" in Package Inserts of New Drugs .... 145
4. ELECTRONIC INFORMATION DISSEMINATION .......................... 145
5. PACKAGE INSERTS OF NON-PRESCRIPTION DRUGS .......................... 145
6. PACKAGE INSERTS OF GUIDANCE-MANDATORY DRUGS .... 146

CHAPTER 6 .................................................. 150
HEALTH INSURANCE PROGRAMS AND DRUG PRICING IN JAPAN .............. 150
   1. HISTORY OF HEALTH INSURANCE PROGRAMS .......................... 150
   2. MEDICAL BENEFITS OFFERED UNDER HEALTH INSURANCE PROGRAMS ........................................ 151
   3. REIMBURSEMENT OF MEDICAL FEES 151
   4. NATIONAL HEALTH INSURANCE PRICE LIST .......................... 152
   5. PRICING FORMULA FOR REIMBURSEMENT PRICE REVISIONS OF DRUGS LISTED IN THE NHI PRICE LIST ........................................ 152
   6. RECENT REVISIONS OF THE NHI PRICE LIST .......................... 154
   7. DETERMINATION OF REIMBURSEMENT PRICES FOR NEW DRUGS ........................................ 155
   8. ENTRY OF GENERIC DRUGS IN THE NHI PRICE LIST .................. 156
   9. ISSUES RELATED TO THE USE OF DETERMINATION OF UNAPPROVED DRUGS AND OFF-LABEL USE .......... 156

Fig. 1 Organization of Ministry of Health, Labour, and Welfare (Health-related organizations only) ........................................ 11
Fig. 2 Organization of Pharmaceutical Safety and Environmental Health Bureau (PSEHB) and Pharmaceuticals and Medical Devices Agency (PMDA) .............. 12
Fig. 3 Organization of the Pharmaceutical Affairs and Food Sanitation Council (PAFSC) ........................................ 14
Fig. 4 Flowchart of Patent-Life Extension .......... 47
Fig. 5 Flowchart of Approval Review .......... 48
Fig. 6 Procedure for manufacturing and marketing approval of drugs for overseas manufacturers in Japan .......... 49
Fig. 7 Flowchart of Drug Listing in Japanese Pharmacopoeia .......... 50
Table 1 List of Main Controlled Substances .................................. 51
Table 2 Divisions of the Pharmaceutical and Food Safety Bureau in Charge of Certification Work ........................................ 52
Fig. 8 Flowchart of New Drug Development and Approval .............. 93
Fig. 9  Timeline of the standard process of new drug approval.......................... 94
Table 3  Data to be Submitted with an Application for Approval to Manufacture/Market: A New Prescription Drug.............................................. 95
Table 4  Data to be Submitted with an Application for a Non-prescription Drug .......................... 97
Table 5  Classification of Clinical Studies According to Objectives.......................... 99
Fig. 10  Organization of ICH Common Technical Documents .......................... 100
Fig. 11  Correlation between Development Phases and Types of Study.................. 101
Table 6  ICH topics and guidelines - Progress of harmonization .......................... 102
Fig. 12  Pharmaceutical Post-marketing Surveillance System................................. 127
Fig. 13  Post-marketing Collection and Reporting of Pharmaceutical Safety Information.......................... 128
Fig. 14  Collection and Reporting of Pharmaceutical Safety Information ................. 129
Fig. 15  Reexamination System.................................................. 130
Fig. 16  Reevaluation System.................................................. 131
Fig. 17  Layout of a Package Insert for a Prescription Drug (with “Warning”) ............ 147
Fig. 18  Standard procedures for revision of package insert (1).......................... 148
Fig. 19  Standard procedures for revision of package insert (2).......................... 149
Fig. 20  Reimbursement Pricing Flow-sheet for New Drugs................................. 158
Fig. 21  Correlation between the Time of Marketing Approval Based on Pharmaceutical Affairs Law and the Time of Entry in the NHI Price List .................... 159
Table 7  Methods of Previous Reimbursement Price Revisions .................... 160
Table 9  Requirements for Applying Premiums ............................................. 166